- Home
- About us
- News
- Events
- EXPORT Export
-
BUY
Buy
Buy
- INVEST Invest
- COUNTRY BRAND Country Brand
-
INFORMATION CENTER
Information center
InformationCenterInformationCenterReports Country reports Department reports Foreign trade reports Product-Destination worksheet Sectors reports Work documentsStatistical information Classification Uruguay XXI Exports Imports Innovative National Effort Macroeconomic Monitor Tools Buyers Exporters Investors
- Contact
-
Languages



Uruguay Best Practices in Pharma Supply Chain 2025
With the participation of the President of the Republic, Yamandú Orsi, on September 10, the sixth edition of Uruguay Best Practices in Pharma Supply Chain, the benchmark event for the pharmaceutical supply chain in Latin America, took place at Criolla Elías Regules.
The president's presence reaffirmed Uruguay's institutional commitment to logistics development as an engine for growth, innovation, and attracting investment. Also in attendance were Minister of Public Health Cristina Lustemberg and Minister of Industry, Energy, and Mining Fernanda Cardona, in support of a dynamic sector with great potential.
Currently, the pharmaceutical sector exceeds US$1 billion in transit. Exports reach US$270 million, with a growing trend, and more than 6,500 people work in activities related to medicines, medical devices, and associated services.
Uruguay combines world-class infrastructure with an active innovation ecosystem, where the concentration of specialized companies and suppliers represents one of its greatest differentiators. In this environment, even global competitors manage to cooperate for the development of the country.
Read the full article here.
Access the Uruguay Pharma Supply Chain 2025 photo gallery here:
Get in touch with us
Event declared of nacional interest
_______________________________________
SPONSORS:
PLATINUM
____________________________
GOLD
____________________________
SILVER
____________________________
Organized by
Uruguay XXI works to promote the internationalization of the Life Sciences sector as a priority area, developing strategies focused on attracting investment, promoting exports and innovative aftercare policies.